NRG
60
18
EMC
56
-3
AMGN
31
-16
PPG
61
-4
CVX
46
8
MCHP
43
-11
GS
78
3
SHW
68
-5
HBI
59
4
DNB
82
-2
RSG
76
2
EW
46
3
SPG
63
7
HCP
62
-8
WY
60
-2
ORLY
66
4
NEM
44
-2
TSCO
48
-3
PSA
63
2
ISRG
74
3
NRG
60
18
EMC
56
-3
AMGN
31
-16
PPG
61
-4
CVX
46
8
MCHP
43
-11
GS
78
3
SHW
68
-5
HBI
59
4
DNB
82
-2
RSG
76
2
EW
46
3
SPG
63
7
HCP
62
-8
WY
60
-2
ORLY
66
4
NEM
44
-2
TSCO
48
-3
PSA
63
2
ISRG
74
3
Financhill
Back

Zevra Therapeutics 10K Form

Buy
67

ZVRA
Zevra Therapeutics

Last Price:
9.49
Seasonality Move:
6.65%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $27.46M
Cash Flow: $-18.14M
Price / Cash Flow: 0
Annual Sales: $1.31
Price / Book: 7.21

Profitability

EPS (TTM): -2.11000
Net Income (TTM): $-89.66M
Gross Margin: $24.52M
Return on Equity: -159.89%
Return on Assets: -56.14%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for ZVRA is 89.28%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 124.96% of Gross Profit Margin.
  • The Research & Development expenses have been 144.95% of Revenue.
  • The Interest Expense is -3.26% of Operating Income.
  • The Net Earning history of ZVRA is -167.69% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 2.88
Quick Ratio: 2.82

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ZVRA Technical Analysis vs Fundamental Analysis

Buy
67
Zevra Therapeutics (ZVRA) is a Buy

Is Zevra Therapeutics a Buy or a Sell?